Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MM
MCID: MYL069
MIFTS: 77

Myeloma, Multiple (MM)

Categories: Blood diseases, Bone diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Myeloma, Multiple

About this section

MalaCards integrated aliases for Myeloma, Multiple:

Name: Myeloma, Multiple 57 37 39
Multiple Myeloma 57 12 74 20 43 58 73 36 29 13 6 42 44 15 17 71 32
Plasma Cell Myeloma 12 20 58 54
Medullary Plasmacytoma 43 58 71
Plasma Cell Dyscrasia 20 43 71
Kahler Disease 20 43 58
Myelomatosis 20 43 58
Multiple Myeloma, Resistance to 57 6
Primary Systemic Amyloidosis 58 71
Primary Amyloidosis 58 71
Multiple Myeloma, Susceptibility to 57
Immunoglobulin Deposition Disease 71
Systemic Al Amyloidosis 58
Light-Chain Amyloidosis 58
Kahler-Bozzolo Disease 43
Plasma Cell Neoplasm 71
Plasma Cell Myelomas 43
Myeloma - Multiple 20
Kahler's Disease 43
Al Amyloidosis 58
Mm 73

Characteristics:

Orphanet epidemiological data:

58
primary systemic amyloidosis
Inheritance: Not applicable;
multiple myeloma
Prevalence: 1-9/100000 (United States),1-9/100000 (Worldwide),1-5/10000 (Europe),1-9/100000 (France),1-9/100000 (Europe),1-9/100000 (Australia); Age of onset: Adult;
al amyloidosis
Inheritance: Not applicable; Prevalence: 1-5/10000 (Europe); Age of onset: Adult;

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation


HPO:

31
myeloma, multiple:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Neuronal diseases Nephrological diseases Bone diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare neurological diseases
Rare renal diseases
Rare systemic and rhumatological diseases
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9538
OMIM® 57 254500
KEGG 36 H00010
ICD9CM 34 203.0
MeSH 44 D009101
NCIt 50 C3242
SNOMED-CT 67 94705007
ICD10 32 C90.0
MESH via Orphanet 45 C531616 D009101
ICD10 via Orphanet 33 C90.0 E85.0 E85.1 more
UMLS via Orphanet 72 C0026764 C0268381
UMLS 71 C0026764 C0268381 C0281479 more
Sources

Summaries for Myeloma, Multiple

About this section
MedlinePlus Genetics : 43 Multiple myeloma is a cancer that develops in the bone marrow, the spongy tissue found in the center of most bones. The bone marrow produces red blood cells, which carry oxygen throughout the body; white blood cells, which form the body's defenses (immune system); and platelets, which are necessary for blood clotting.Multiple myeloma is characterized by abnormalities in plasma cells, a type of white blood cell. These abnormal cells multiply out of control, increasing from about one percent of cells in the bone marrow to the majority of bone marrow cells. The abnormal cells form tumors within the bone, causing bone pain and an increased risk of fractures. If the tumors interfere with nerves near the bones, numbness or weakness in the arms or legs can occur. Affected individuals may also experience a loss of bone tissue, particularly in the skull, spine, ribs, and pelvis. The deterioration of bone can result in an excess of calcium in the blood (hypercalcemia), which can lead to nausea and loss of appetite, excessive thirst, fatigue, muscle weakness, and confusion.The abnormal plasma cells in multiple myeloma produce proteins that impair the development of normal blood cells. As a result, affected individuals may have a reduced number of red blood cells (anemia), which can cause fatigue, weakness, and unusually pale skin (pallor); a low number of white blood cells (leukopenia), which can result in a weakened immune system and frequent infections such as pneumonia; and a reduced number of platelets (thrombocytopenia), which can lead to abnormal bleeding and bruising. Kidney problems can also occur in this disorder, caused by hypercalcemia or by toxic proteins produced by the abnormal plasma cells.People with multiple myeloma typically develop the disorder around age 65. Over time, affected individuals can develop life-threatening complications, but the rate at which this happens varies widely. Some affected individuals are diagnosed incidentally when tests are done for other purposes and do not experience symptoms for years.

MalaCards based summary : Myeloma, Multiple, also known as multiple myeloma, is related to monoclonal gammopathy of uncertain significance and plasma cell leukemia. An important gene associated with Myeloma, Multiple is LIG4 (DNA Ligase 4), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Phentolamine and Ofloxacin have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are osteopenia and pathologic fracture

Disease Ontology : 12 A myeloid neoplasm that is located in the plasma cells in bone marrow.

GARD : 20 Multiple myeloma is a form of cancer that occurs due to abnormal and uncontrolled growth of plasma cells in the bone marrow. Some people with multiple myeloma, especially those with early stages of the condition, have no concerning signs or symptoms. When present, the most common symptom is anemia, which can be associated with fatigue and shortness of breath. Other features of the condition may include multiple infections; abnormal bleeding; bone pain; weak and/or easily broken bones; and numbness and/or weakness of the arms and legs. The exact underlying cause of multiple myeloma is currently unknown. Factors that are associated with an increased risk of developing multiple myeloma include increasing age, male sex, African American race, radiation exposure, a family history of the condition, obesity, and/or a personal history of monoclonal gammopathy of undetermined significance (MGUS). Treatment varies based on many factors, but may include one or more of the following interventions: chemotherapy, corticosteroid medications, targeted therapy, stem cell transplant, biological therapy, radiation therapy, surgery and/or watchful waiting.

OMIM® : 57 Multiple myeloma is a neoplastic plasma cell disorder characterized by clonal proliferation of malignant plasma cells in the bone marrow microenvironment, monoclonal protein in the blood or urine, and associated organ dysfunction (Palumbo and Anderson, 2011). (254500) (Updated 05-Mar-2021)

MedlinePlus : 42 Multiple myeloma is a cancer that begins in plasma cells, a type of white blood cell. These cells are part of your immune system, which helps protect the body from germs and other harmful substances. In time, myeloma cells collect in the bone marrow and in the solid parts of bones. No one knows the exact causes of multiple myeloma, but it is more common in older people and African Americans. It can run in families. Common symptoms may include Bone pain, often in the back or ribs Fractures (broken bones) Weakness or fatigue Weight loss Frequent infections and fevers Feeling very thirsty Frequent urination Doctors diagnose multiple myeloma using lab tests, imaging tests, and a bone marrow biopsy. Your treatment depends on how advanced the disease is and whether you have symptoms. If you have no symptoms, you may not need treatment right away. If you have symptoms, you may have chemotherapy, stem cell transplantation, radiation, or targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

KEGG : 36 Multiple myeloma is a disorder in which malignant plasma cells accumulate, generally derived from one clone in the bone marrow. Intricate interactions occur between the bone-marrow microenvironment and the myeloma cells, frequently causing bone destruction, which in turn stimulates tumor growth. Often it is preceded by a premalignant tumor called monoclonal gammopathy of undetermined significance (MGUS). Multiple oncogenic events have been identified that have contributed to the pathogenesis of myeloma. Among the earliest genetic events are translocations of the immunoglobulin heavy-chain gene locus, which leads to dysregulation of oncogenes at translocation partner regions (cyclin D1 at 11q13, FGFR3/MMSET at 4p16.3, c-MAF at 16q23, and cyclin D3 at 6p21), and deletions of 13q14, the site of a putative tumor suppressor gene. Additional molecular events include epigenetic changes and activation of oncogenes (mutations of N-RAS and K-RAS, and changes in c-MYC), which are usually associated with disease progression.

UniProtKB/Swiss-Prot : 73 Multiple myeloma: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia.

Wikipedia : 74 Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma... more...

Sources

Related Diseases for Myeloma, Multiple

About this section

Diseases related to Myeloma, Multiple via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1413)
# Related Disease Score Top Affiliating Genes
1 monoclonal gammopathy of uncertain significance 33.3 MIR19A FGFR3 CCND1
2 plasma cell leukemia 33.2 MIR19A KRAS FGFR3 CCND1
3 plasma cell neoplasm 33.1 PVT1 LIG4 KRAS FGFR3
4 leukemia, chronic lymphocytic 32.4 MIR19A MIR181A2 MIR15A MIR106B KRAS CCND1
5 leukemia, acute myeloid 32.4 UCA1 TUG1 MIR181A2 MIR106B KRAS HOTAIR
6 b-cell lymphoma 32.2 TUG1 PVT1 HOTAIR GAS5 CCND1
7 renal cell carcinoma, nonpapillary 32.0 UCA1 TUG1 PVT1 MIR93 MIR15A MIR106B
8 prostate cancer 32.0 UCA1 TUG1 PVT1 PCAT1 MIR32 MIR25
9 hematologic cancer 31.9 PVT1 MIR93 MIR25 MIR19A MIR15A
10 melanoma 31.9 UCA1 PVT1 MIR19A MIR181A2 MIR15A KRAS
11 lung cancer 31.8 UCA1 TUG1 PVT1 PCAT1 MIR93 MIR32
12 hepatocellular carcinoma 31.8 UCA1 TUG1 PVT1 PCAT1 MIR93 MIR25
13 colorectal cancer 31.7 UCA1 TUG1 PVT1 PCAT1 MIR93 MIR32
14 bladder cancer 31.7 UCA1 TUG1 PVT1 PCAT1 KRAS HOTAIR
15 pancreatic cancer 31.7 UCA1 TUG1 PVT1 MIR32 MIR25 MIR181A2
16 gastric cancer 31.7 UCA1 TUG1 PVT1 PCAT1 MIR93 MIR25
17 lung cancer susceptibility 3 31.7 TUG1 MIR15A KRAS HOTAIR GAS5 FGFR3
18 osteogenic sarcoma 31.6 UCA1 TUG1 PVT1 PCAT1 HOTAIR GAS5
19 glioblastoma 31.5 TUG1 PCAT1 MIR25 MIR181A2 HOTAIR GAS5
20 thyroid carcinoma 31.4 UCA1 PVT1 HOTAIR GAS5
21 squamous cell carcinoma 31.4 UCA1 TUG1 PCAT1 HOTAIR FGFR3 CCND1
22 endometrial cancer 31.4 UCA1 TUG1 KRAS HOTAIR GAS5 CCND1
23 kidney cancer 31.3 PVT1 MIR15A MIR106B HOTAIR GAS5
24 ovarian cancer 31.3 UCA1 TUG1 PVT1 MIR25 MIR106B KRAS
25 glioma 31.3 UCA1 PVT1 MIR25 MIR19A MIR181A2 MIR15A
26 nervous system disease 31.3 MIR93 MIR32 MIR25 MIR19A MIR15A MIR106B
27 esophageal cancer 31.2 UCA1 PVT1 PCAT1 MIR93 KRAS HOTAIR
28 cervical cancer 31.1 UCA1 TUG1 PVT1 PCAT1 MIR93 MIR15A
29 intrahepatic cholangiocarcinoma 31.1 TUG1 KRAS CCND1 CCAT1
30 cholangiocarcinoma 31.1 UCA1 TUG1 PCAT1 KRAS
31 nasopharyngeal carcinoma 31.0 PVT1 MIR93 HOTAIR GAS5 CCND1 CCAT1
32 retinitis pigmentosa 11 31.0 UCA1 TUG1 PVT1 HOTAIR GAS5
33 high grade glioma 31.0 TUG1 PVT1 HOTAIR GAS5 CCAT1
34 gastrointestinal stromal tumor 30.9 KRAS HOTAIR FGFR3 CCND1
35 bladder urothelial carcinoma 30.9 TUG1 PVT1 KRAS HOTAIR GAS5 FGFR3
36 arteries, anomalies of 30.9 MIR93 MIR25 MIR15A MIR106B
37 clear cell renal cell carcinoma 30.9 TUG1 PVT1 MIR106B CCND1
38 oral squamous cell carcinoma 30.8 UCA1 TUG1 MIR19A HOTAIR CCND1 CCAT1
39 central nervous system disease 30.8 MIR93 MIR25 MIR15A MIR106B
40 nervous system cancer 30.8 MIR93 MIR25 MIR19A MIR15A CCND1
41 gallbladder cancer 30.8 UCA1 TUG1 KRAS HOTAIR CCAT1
42 colonic benign neoplasm 30.6 MIR15A KRAS CCND1
43 rosai-dorfman disease 30.6 KRAS CCND1
44 medulloblastoma 30.1 MIR19A LIG4 HOTAIR CCND1 CCAT1
45 light chain deposition disease 11.4
46 primary localized amyloidosis 11.2
47 smoldering myeloma 11.2
48 plasmacytoma 11.2
49 bone disease 11.1
50 lymphoplasmacytic lymphoma 11.1

Graphical network of the top 20 diseases related to Myeloma, Multiple:



Diseases related to Myeloma, Multiple
Sources

Symptoms & Phenotypes for Myeloma, Multiple

About this section

Human phenotypes related to Myeloma, Multiple:

58 31 (show top 50) (show all 82)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 osteopenia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000938
2 pathologic fracture 58 31 hallmark (90%) Very frequent (99-80%) HP:0002756
3 nephropathy 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000112
4 fatigue 58 31 frequent (33%) Frequent (79-30%),Very frequent (99-80%) HP:0012378
5 anemia 58 31 frequent (33%) Frequent (79-30%) HP:0001903
6 nephrotic syndrome 58 31 frequent (33%) Frequent (79-30%),Frequent (79-30%) HP:0000100
7 bone pain 58 31 frequent (33%) Frequent (79-30%) HP:0002653
8 generalized muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0003324
9 acute kidney injury 58 31 frequent (33%) Frequent (79-30%) HP:0001919
10 elevated serum creatinine 58 31 frequent (33%) Frequent (79-30%) HP:0003259
11 hyperproteinemia 58 31 frequent (33%) Frequent (79-30%) HP:0002152
12 increased circulating igg level 58 31 frequent (33%) Frequent (79-30%) HP:0003237
13 decreased circulating antibody level 31 frequent (33%) HP:0004313
14 paresthesia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003401
15 abnormality of the bladder 58 31 occasional (7.5%) Occasional (29-5%) HP:0000014
16 hypercalcemia 58 31 occasional (7.5%) Occasional (29-5%) HP:0003072
17 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
18 tall stature 58 31 occasional (7.5%) Occasional (29-5%) HP:0000098
19 vertebral compression fractures 58 31 occasional (7.5%) Occasional (29-5%) HP:0002953
20 functional abnormality of the gastrointestinal tract 58 31 occasional (7.5%) Occasional (29-5%) HP:0012719
21 spinal cord compression 58 31 occasional (7.5%) Occasional (29-5%) HP:0002176
22 increased circulating iga level 58 31 occasional (7.5%) Occasional (29-5%) HP:0003261
23 abnormality of vitamin b12 metabolism 58 31 occasional (7.5%) Occasional (29-5%) HP:0004341
24 splenomegaly 58 31 very rare (1%) Very rare (<4-1%) HP:0001744
25 pleural effusion 58 31 very rare (1%) Very rare (<4-1%),Occasional (29-5%) HP:0002202
26 lymphadenopathy 58 31 very rare (1%) Very rare (<4-1%),Frequent (79-30%) HP:0002716
27 multiple myeloma 58 31 Frequent (79-30%) HP:0006775
28 constipation 58 Frequent (79-30%)
29 hypertension 58 Occasional (29-5%)
30 macroglossia 58 Occasional (29-5%)
31 hepatomegaly 58 Frequent (79-30%)
32 malabsorption 58 Occasional (29-5%)
33 proteinuria 58 Frequent (79-30%)
34 renal insufficiency 58 Frequent (79-30%)
35 congestive heart failure 58 Frequent (79-30%)
36 hepatitis 58 Occasional (29-5%)
37 hypertrophic cardiomyopathy 58 Very frequent (99-80%)
38 decreased antibody level in blood 58 Frequent (79-30%),Occasional (29-5%)
39 hematuria 58 Occasional (29-5%)
40 dyspnea 58 Frequent (79-30%)
41 arthralgia 58 Frequent (79-30%)
42 arrhythmia 58 Frequent (79-30%)
43 purpura 58 Occasional (29-5%)
44 gastrointestinal hemorrhage 58 Occasional (29-5%)
45 osteoarthritis 58 Occasional (29-5%)
46 skeletal muscle hypertrophy 58 Occasional (29-5%)
47 goiter 58 Occasional (29-5%)
48 papule 58 Occasional (29-5%)
49 enlarged kidney 58 Frequent (79-30%)
50 keratoconjunctivitis sicca 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
multiple myeloma

Laboratory Abnormalities:
paraproteinemia
high m-component
monoclonal gammopathy
primary immunoglobulin-related amyloidosis (al)

Clinical features from OMIM®:

254500 (Updated 05-Mar-2021)

Sources

Drugs & Therapeutics for Myeloma, Multiple

About this section

Drugs for Myeloma, Multiple (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 567)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phentolamine Approved Phase 4 50-60-2 5775
2
Ofloxacin Approved Phase 4 82419-36-1 4583
3
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
4
Iron Approved Phase 4 7439-89-6 23925 29936
5
Pirarubicin Investigational Phase 4 72496-41-4
6 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
7 Hematinics Phase 4
8 Epoetin alfa Phase 4 113427-24-0
9
Apixaban Approved Phase 3 503612-47-3 10182969
10
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
11
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
12
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
13
Ifosfamide Approved Phase 3 3778-73-2 3690
14
Sulfamethoxazole Approved Phase 3 723-46-6 5329
15
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
16
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
20
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
21
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
22
Denosumab Approved Phase 3 615258-40-7
23
Pamidronate Approved Phase 3 40391-99-9 4674
24
Carvedilol Approved, Investigational Phase 3 72956-09-3 2585
25
Enalaprilat Approved Phase 3 76420-72-9 6917719
26
Enalapril Approved, Vet_approved Phase 3 75847-73-3 5362032 40466924
27
Idarubicin Approved Phase 3 58957-92-9 42890
28
Epirubicin Approved Phase 3 56420-45-2 41867
29
Nystatin Approved, Vet_approved Phase 3 1400-61-9 11953884
30
deoxycholic acid Approved Phase 3 83-44-3 222528
31
Tazobactam Approved Phase 3 89786-04-9 123630
32
Piperacillin Approved Phase 3 66258-76-2 43672
33
Vancomycin Approved Phase 3 1404-90-6 441141 14969
34
Amitriptyline Approved Phase 3 50-48-6 2160
35
Baclofen Approved Phase 3 1134-47-0 2284
36
Perphenazine Approved Phase 3 58-39-9 4748
37
Morphine Approved, Investigational Phase 3 57-27-2 5288826
38
Oxycodone Approved, Illicit, Investigational Phase 3 76-42-6 5284603
39
Doxycycline Approved, Investigational, Vet_approved Phase 2, Phase 3 564-25-0 54671203
40
Rivaroxaban Approved Phase 2, Phase 3 366789-02-8
41
Ketorolac Approved Phase 3 74103-06-3, 66635-83-4 3826
42
Hydrocodone Approved, Illicit, Investigational Phase 3 125-29-1 5284569
43
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
44
Venetoclax Approved, Investigational Phase 3 1257044-40-8 49846579
45
Cytarabine Approved, Investigational Phase 3 147-94-4 6253
46
Dalteparin Approved Phase 3 9005-49-6
47
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
48
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
49
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
50
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946

Interventional clinical trials:

(show top 50) (show all 2751)
# Name Status NCT ID Phase Drugs
1 A Multicenter, Double Arms, Prospective Phase 4 Study to Evaluating the Efficacy and Safety of Combination Therapy of PAD Versus VCD Treatment in Previously Untreated Subjects With Multiple Myeloma. Unknown status NCT01868828 Phase 4 PAD;VCD
2 Stage I Multiple Myeloma Treatment Unknown status NCT00733538 Phase 4 zometa
3 Study of Efficacy of PAD-regimen(Bortezomib,Pirarubicin and Dexamethasone) and TAD-regimen(Thalidomide,Pirarubicin and Dexamethasone) in Newly Diagnosed Multiple Myeloma,Influence in Concentration of Bone Metabolites,and the Relations With Different Cytogenetic and Molecular Biological Changes Unknown status NCT01249690 Phase 4 Bortezomib,Pirarubicin,Dexamethasone;Thalidomide,Pirarubicin,Dexamethasone
4 An Open-Label Phase IV Study of the Efficacy of Bortezomib-based Combination Therapy the Treatment of Subjects With Multiple Myeloma Unknown status NCT02559154 Phase 4 Bortezomib;Dexamethasone;Doxorubicin;Cyclophosphamide;Mitoxsnteone;Thalidomide
5 A Randomized Clinical Trial of Lenalidomide (CC-5013) and Dexamethasone With and Without Autologous Peripheral Blood Stem Cell Transplant in Patients With Newly Diagnosed Multiple Myeloma Completed NCT01731886 Phase 4 Lenalidomide;Dexamethasone;Melphalan;G-CSF;Cyclophosphamide;Mesna
6 A Prospective, Multicenter, Open-label Clinical Evaluation of the Effect of IV Zoledronic Acid 4mg on PAIN, QUALITY OF LIFE and TIME IN INFUSION CHAIR in Breast Cancer, Multiple Myeloma, and Prostate Cancer Patients With Cancer-related Bone Lesions Completed NCT00029224 Phase 4 zoledronic acid
7 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Receiving Immunomodulatory Therapy Completed NCT02958969 Phase 4 Apixaban
8 Assessment of the Antitumour Effect of Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse: Prospective Clinical Trial of the GEM/PETHEMA Group Completed NCT01087008 Phase 4 zoledronic acid
9 A Multicenter,Open Label, Randomized Trial Evaluating the Duration of Infusion of Zoledronic Acid 4 mg IV in Multiple Myeloma Patients With Bone Metastases Completed NCT00104104 Phase 4 zoledronic acid
10 Evaluation of VELCADE (Botezomib) for Injection Employed as Re-Treatment for Efficacy, Safety, and Tolerability Completed NCT00257114 Phase 4 bortezomib
11 Thalidomide-Cyclophosphamide-Dexamethasone in Patients < 75 Years or Velcade-Melfalan-Prednisone (V-MP)/Thalidomide-Cyclophosphamide-Dexamethasone in Patients >75 Years, in Refractary or Relapsed Multiple Myeloma Completed NCT00652041 Phase 4 Bortezomib;Thalidomide;Bortezomib
12 Bone Marker Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Advanced Multiple Myeloma Completed NCT00622505 Phase 4 zoledronic acid
13 Pharmacokinetic Study of Bortezomib (VELCADE) Administered Intravenously in Taiwanese Patients With Multiple Myeloma - A Post Approval Commitment Study Completed NCT02268890 Phase 4 Bortezomib
14 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
15 An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation Completed NCT00352703 Phase 4 Kepivance (Palifermin)
16 REmoval of Free Light Chains in Hemodialysis Patients Without Multiple Myeloma. A Crossover COmpaRison of Three Different dialyzERs Completed NCT02950389 Phase 4
17 The Effects of PROCRIT (Epoetin Alfa) on Hemoglobin, Symptom Distress, and Quality of Life During Chemotherapy in Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma Patients With Mild to Moderate Anemia Completed NCT00524407 Phase 4 Epoetin alfa
18 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
19 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma Recruiting NCT03908138 Phase 4 RDD;VDD
21 Influenza Vaccination in Plasma Cell Dyscrasias Recruiting NCT04080531 Phase 4
22 A Comparative Study of Bortezomib-Thalidomide-Dexamethason and Bortezomib-Cyclophosphamide-Dexamethason in the Treatment of Monoclonal Immunoglobulin Light Chain Amyloidosis: A Prospective Randomized Controlled Trial（BTD-CHINA-TRIAL） Recruiting NCT04612582 Phase 4 Thalidomide;Cyclophosphamide
23 Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients Recruiting NCT04348006 Phase 4 Bortezomib 3.5 MG
24 A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent Recruiting NCT03768960 Phase 4 Daratumumab
25 A RANDOMIZED, MULTICENTER, OPEN LABEL STUDY COMPARING TWO STANDARD TREATMENTS, BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS LENALIDOMIDE-DEXAMETHASONE (Rd) IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) INELIGIBLE COMMUNITY POPULATION AFFECTED BY MULTIPLE MYELOMA (MM) Recruiting NCT03829371 Phase 4 Velcade;Melphalan;Prednisone;Lenalidomide;Dexamethasone
26 Magnolia Study Prolonged Protection From Bone Disease in Multiple Myeloma. An Open Label Phase 3 Multicenter International Randomised Trial Recruiting NCT02286830 Phase 4 Zoledronic acid
27 Post-marketing Phase 4 Study to Evaluate Safety, Tolerability, and Efficacy of Kyprolis® (Carfilzomib) in Indian Patients With Relapsed or Refractory Multiple Myeloma: A Prospective, Open-label, Non-comparative, Multicenter Study Recruiting NCT03934684 Phase 4 Drug: Carfilzomib + Dexamethasone;Drug: Carfilzomib + Lenalidomide + Dexamethasone
28 An Open-Label, Single-Arm, Multicenter Study to Evaluate the Effectiveness and Safety of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) in Patients With Multiple Myeloma Previously Receiving a Bortezomib-Based Induction Regimen (US MM-6) Recruiting NCT03173092 Phase 4 Ixazomib;Lenalidomide;Dexamethasone
29 A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma Recruiting NCT04217967 Phase 4 Ixazomib;Lenalidomide
30 Doxorubicin Hydrochloride Liposome vs Doxorubicin Combined With Bortizomib and Dexamethasone to Treat Initially Diagnosed Multiple Myeloma: A Randomized Prospective Clinical Study Active, not recruiting NCT02577783 Phase 4 PDD regimen: doxorubicin hydrochloride iposome, bortizomib and dexamethasone;PAD regimen: bortizomib, dexamethasone and doxorubicin
31 An Open-label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Active, not recruiting NCT03416374 Phase 4 Ixazomib;Bortezomib;Carfilzomib;Lenalidomide;Dexamethasone
32 Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents Enrolling by invitation NCT03619252 Phase 4 Standard Antibacterial Prophylaxis
33 Clinical, Multicenter, Single-arm, Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma (MM) Newly Diagnosed Symptomatic ≥75 Years Terminated NCT02773550 Phase 4 Bortezomib;Melphalan;Prednisone
34 Randomised Controlled Open-label Study to Evaluate Efficacy & Safety of Intravenous Ferric Carboxymaltose Versus no Treatment in Anaemic Subjects With Multiple Myeloma & Iron Restricted Erythropoiesis Receiving Chemotherapy Terminated NCT01100879 Phase 4 Ferric carboxymaltose
35 Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment Terminated NCT02608060 Phase 4 Epoetin Beta
36 Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma Withdrawn NCT01410929 Phase 4
37 Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. Withdrawn NCT00242528 Phase 4 Zoledronic acid
38 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
39 Iberoamerican Phase III International Study, Open, Multicenter, Randomized, Comparative of Thalidomide / Cyclophosphamide / Dexamethasone Versus Thalidomide / Dexamethasone Versus Thalidomide / Melphalan / Prednisone as Induction Therapy Followed by Maintenance Therapy With Thalidomide + Prednisone Versus Thalidomide Alone in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65years. Unknown status NCT01532856 Phase 3 Thalidomide, Cyclophosphamide, Dexamethasone;Thalidomide, Dexamethasone;Thalidomide, Melphalan, Prednisone
40 A Phase 3 Trial Comparing Cyclophosphamide,Bortezomib,and Dexamethasone (CyBorD) and Bortezomib,Doxorubicin,and Dexamethasone (PAD) in the Treatment of Newly Diagnosed Multiple Myeloma Unknown status NCT02362165 Phase 3 Cyclophosphamide;Bortezomib;Dexamethasone;Doxorubicin
41 Clarithromycin Plus CTd (Cyclophosphamide,Thalidomide and Dexamethasone)Regimen for Patients With Newly Diagnosed Multiple Myeloma:a Phase 3 , Multicenter,Randomized, Open-Label Trial. Unknown status NCT02248428 Phase 3 Clarithromycin;Thalidomide;Cyclophosphamide;Dexamethasone
42 A Phase 3 Study of Velcade (Bortezomib) Dexamethasone (VD) Versus Velcade (Bortezomib) Thalidomide Dexamethasone (VTD) as an Induction Treatment Prior to Autologous Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma Unknown status NCT00910897 Phase 3 Velcade-Dexamethasone;Velcade-Thalidomide-Dexamethasone
43 VIIITH MYELOMATOSIS TRIAL: A RANDOMISED TRIAL OF TREATMENT FOR INDUCING FIRST PLATEAU PHASE ABCM VS 3 COURSES OF ABCM FOLLOWED BY ORAL WEEKLY CYCLOPHOSPHAMIDE Unknown status NCT00002653 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;prednisone
44 MYELOMA VII MEDICAL RESEARCH COUNCIL WORKING PARTY ON LEUKEMIA IN ADULTS: MYELOMATOSIS THERAPY TRIAL Unknown status NCT00002599 Phase 3 carmustine;cyclophosphamide;doxorubicin hydrochloride;melphalan;methylprednisolone;prednisone;vincristine sulfate
45 A Randomized, Phase III, Placebo-Controlled Multicenter Study to Demonstrate the Effectiveness and Safety of the Combination Enzyme Tablet (Wobe-Mugos E) as Adjuvant Therapy to Standard of Care Treatment in Patients With Stages II or III Multiple Myeloma Unknown status NCT00014339 Phase 3 Wobe-Mugos E;melphalan;prednisone
46 Myeloma X Relapse (Intensive): A Phase III Study to Determine the Role of a Second Autologous Stem Cell Transplant as Consolidation Therapy in Patients With Relapsed Multiple Myeloma Following Prior High-dose Chemotherapy and Autologous Stem Cell Rescue. Unknown status NCT00747877 Phase 3 cyclophosphamide;melphalan
47 A Randomized Phase III Study On The Effect Of Thalidomide Combined With Adriamycin, Dexamethasone (AD) And High Dose Melphalan In Patients With Multiple Myeloma Unknown status NCT00028886 Phase 3 cyclophosphamide;dexamethasone;doxorubicin hydrochloride;melphalan;thalidomide;vincristine sulfate
48 A Randomised Study Comparing CIDEX (CCNU, Oral Idarubicin and Dexamethasone) With Melphalan and Prednisolone in Relapsed Multiple Myeloma Unknown status NCT00003603 Phase 3 cyclophosphamide;dexamethasone;idarubicin;lomustine;melphalan;prednisolone
49 Comparable Investigation of One Fraction Radiotherapy (8 Gy x 1) and Multifraction Radiotherapy (3 Gy x 10) of Painful Bone Destructions in Patients With Multiple Myeloma. Unknown status NCT02024815 Phase 3
50 Multizentrische Therapiestudie Des Multiplen Myeloms DSMM V Therapieoptimierungs-Studie Der Deutschen Studiengruppe Multiples Myelom für Patienten Bis 60 Jahre im Stadium II/III Unknown status NCT00546988 Phase 3

Search NIH Clinical Center for Myeloma, Multiple

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Aldesleukin
bortezomib
carfilzomib
Carmustine
Cisplatin
CISPLATIN PWDR
Cyclophosphamide
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Melphalan
Melphalan hydrochloride
panobinostat
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b
Thalidomide
ZOLEDRONIC
zoledronic acid

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myeloma, Multiple cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myeloma, Multiple:
Blood stem cell transplantation for hematological diseases
Hematopoietic stem cells for treatment of hematologic malignancies
Peripheral blood stem cells for treatment of hematologic malignancies
Embryonic/Adult Cultured Cells Related to Myeloma, Multiple:
Peripheral blood-derived hematopoietic stem cells (family)
Bone marrow-derived hematopoietic stem cells

Cochrane evidence based reviews: multiple myeloma

Sources

Genetic Tests for Myeloma, Multiple

About this section

Genetic tests related to Myeloma, Multiple:

# Genetic test Affiliating Genes
1 Multiple Myeloma 29 CCND1 LIG4
Sources

Anatomical Context for Myeloma, Multiple

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Myeloma, Multiple:

19
Plasma Cells In Bone Marrow

MalaCards organs/tissues related to Myeloma, Multiple:

40
Bone, Bone Marrow, T Cells, Myeloid, Kidney, Breast, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Myeloma, Multiple:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
Sources

Publications for Myeloma, Multiple

About this section

Articles related to Myeloma, Multiple:

(show top 50) (show all 30051)
# Title Authors PMID Year
1
Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. 61 6 57
12471202 2002
2
Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. 6 57 61
9207791 1997
3
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism. 61 57
28903037 2017
4
BCL-B (BCL2L10) is overexpressed in patients suffering from multiple myeloma (MM) and drives an MM-like disease in transgenic mice. 61 57
27455953 2016
5
The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma. 57 61
23502783 2013
6
Initial genome sequencing and analysis of multiple myeloma. 61 57
21430775 2011
7
Multiple myeloma. 57 61
21410373 2011
8
Association of a dominantly inherited hyperphosphorylated paraprotein target with sporadic and familial multiple myeloma and monoclonal gammopathy of undetermined significance: a case-control study. 57 61
19767238 2009
9
A frequent target of paraproteins in the sera of patients with multiple myeloma and MGUS. 61 57
19405124 2009
10
Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. 57 61
18594024 2008
11
Familial myeloma. 57 61
18614782 2008
12
IRF4 addiction in multiple myeloma. 61 57
18568025 2008
13
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes. 57 61
17654686 2007
14
Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14). 61 6
11529856 2001
15
Familial multiple myeloma: report of fifteen families. 57 61
10354144 1999
16
Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. 57 61
9326949 1997
17
Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma. 61 57
8943038 1996
18
Multiple myeloma in a pair of twins. 61 57
3814524 1987
19
Multiple myeloma in three siblings. 57 61
3927866 1985
20
Multiple myeloma in a pair of monozygotic twins: the first reported case. 61 57
3925983 1985
21
MULTIPLE MYELOMA IN SIBLINGS. 61 57
14180901 1964
22
KORNGOLD L: MULTIPLE MYELOMA IN 2 SISTERS. AN IMMUNOCHEMICAL STUDY. 57 61
14172080 1964
23
Multiple myeloma in sisters. 61 57
13766287 1961
24
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial. 61 42
33357482 2021
25
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study. 42 61
33301738 2021
26
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects. 61 42
33275634 2020
27
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. 61 47
19846888 2009
28
Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. 6
19855393 2009
29
MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. 47 61
19401561 2009
30
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. 61 47
18728182 2008
31
An epidermal nevus syndrome with cerebral involvement caused by a mosaic FGFR3 mutation. 6
18642369 2008
32
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma. 61 47
18700954 2008
33
Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi. 6
16841094 2006
34
Thanatophoric dysplasia type 2 with encephalocele during the second trimester. 6
16752380 2006
35
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
36
Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. 57
14739213 2004
37
Somatic and germline mosaicism for a R248C missense mutation in FGFR3, resulting in a skeletal dysplasia distinct from thanatophoric dysplasia. 6
12833394 2003
38
The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. 6
12624096 2003
39
Translocations of 14q32 and deletions of 13q14 are common chromosomal abnormalities in systemic amyloidosis. 57
11972529 2002
40
Prenatal diagnosis of thanatophoric dysplasia by mutational analysis of the fibroblast growth factor receptor 3 gene and a proposed correction of previously published PCR results. 6
10073901 1999
41
Anticipation in familial plasma cell dyscrasias. 57
9858219 1998
42
Molecular, radiologic, and histopathologic correlations in thanatophoric dysplasia. 6
9677066 1998
43
Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1. 57
9482902 1998
44
The systemic amyloidoses. 57
9302305 1997
45
Japanese cases of type 1 thanatophoric dysplasia exclusively carry a C to T transition at nucleotide 742 of the fibroblast growth factor receptor 3 gene. 6
8858131 1996
46
Familial AL-amyloidosis in three Italian siblings. 57
8641636 1996
47
Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3. 6
7773297 1995
48
IgM monoclonal gammopathy and neuropathy in two siblings. 57
2852210 1988
49
Primary amyloidosis (AL) in families. 57
3706293 1986
50
[Familial IgG kappa myeloma in a mother and her daughter. Review of the literature]. 57
3086836 1986
Sources

Variations for Myeloma, Multiple

About this section

ClinVar genetic disease variations for Myeloma, Multiple:

6 (show top 50) (show all 197)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 LIG4 NM_206937.2(LIG4):c.8C>T (p.Ala3Val) SNV protective 7676 rs1805389 13:108863609-108863609 13:108211261-108211261
2 LIG4 NM_206937.2(LIG4):c.26C>T (p.Thr9Ile) SNV protective 7677 rs1805388 13:108863591-108863591 13:108211243-108211243
3 KRAS NM_004985.5(KRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic 45122 rs121913529 12:25398284-25398284 12:25245350-25245350
4 FGFR3 FGFR3, FGFR3/IGH FUSION Variation Pathogenic 16343
5 FGFR3 NM_000142.5(FGFR3):c.1948A>G (p.Lys650Glu) SNV Pathogenic 16331 rs78311289 4:1807889-1807889 4:1806162-1806162
6 LIG4 NM_206937.2(LIG4):c.2440C>T (p.Arg814Ter) SNV Pathogenic 7673 rs104894419 13:108861177-108861177 13:108208829-108208829
7 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic/Likely pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
8 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Likely pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
9 HRAS NM_005343.4(HRAS):c.436G>A (p.Ala146Thr) SNV Likely pathogenic 12607 rs104894231 11:533467-533467 11:533467-533467
10 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg) SNV Likely pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
11 TP53 NM_000546.6(TP53):c.396G>C (p.Lys132Asn) SNV Likely pathogenic 376624 rs866775781 17:7578534-7578534 17:7675216-7675216
12 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe) SNV Likely pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
13 TP53 NM_000546.5(TP53):c.395A>G (p.Lys132Arg) SNV Likely pathogenic 376625 rs1057519996 17:7578535-7578535 17:7675217-7675217
14 BRAF NM_001374258.1(BRAF):c.1907G>T (p.Gly636Val) SNV Likely pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
15 TP53 NM_000546.6(TP53):c.818G>A (p.Arg273His) SNV Likely pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
16 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Likely pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
17 TP53 NM_000546.5(TP53):c.394A>G (p.Lys132Glu) SNV Likely pathogenic 376626 rs747342068 17:7578536-7578536 17:7675218-7675218
18 TP53 NM_001126115.1(TP53):c.-2A>C SNV Likely pathogenic 376627 rs1057519996 17:7578535-7578535 17:7675217-7675217
19 TP53 NM_000546.6(TP53):c.451C>T (p.Pro151Ser) SNV Likely pathogenic 12370 rs28934874 17:7578479-7578479 17:7675161-7675161
20 HRAS NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Likely pathogenic 180848 rs104894226 11:534285-534285 11:534285-534285
21 CDK4 NM_000075.4(CDK4):c.70C>T (p.Arg24Cys) SNV Likely pathogenic 16928 rs11547328 12:58145431-58145431 12:57751648-57751648
22 HRAS NM_005343.4(HRAS):c.437C>T (p.Ala146Val) SNV Likely pathogenic 12611 rs121917759 11:533466-533466 11:533466-533466
23 PIK3CA NM_006218.4(PIK3CA):c.333G>C (p.Lys111Asn) SNV Likely pathogenic 376483 rs1057519934 3:178916946-178916946 3:179199158-179199158
24 TP53 NM_001276697.2(TP53):c.-27C>G SNV Likely pathogenic 376641 rs28934874 17:7578479-7578479 17:7675161-7675161
25 HRAS NM_005343.4(HRAS):c.436G>C (p.Ala146Pro) SNV Likely pathogenic 376442 rs104894231 11:533467-533467 11:533467-533467
26 TP53 NM_001276697.2(TP53):c.-26C>G SNV Likely pathogenic 376640 rs1057520000 17:7578478-7578478 17:7675160-7675160
27 BRAF NM_001374258.1(BRAF):c.1919T>A (p.Val640Glu) SNV Likely pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
28 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Likely pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
29 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg) SNV Likely pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
30 PIK3CA NM_006218.4(PIK3CA):c.332A>G (p.Lys111Arg) SNV Likely pathogenic 376484 rs1057519935 3:178916945-178916945 3:179199157-179199157
31 TP53 NM_000546.5(TP53):c.712T>G (p.Cys238Gly) SNV Likely pathogenic 376577 rs1057519981 17:7577569-7577569 17:7674251-7674251
32 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
33 PIK3CA NM_006218.4(PIK3CA):c.331A>G (p.Lys111Glu) SNV Likely pathogenic 376482 rs1057519933 3:178916944-178916944 3:179199156-179199156
34 TP53 NM_000546.5(TP53):c.713G>A (p.Cys238Tyr) SNV Likely pathogenic 182935 rs730882005 17:7577568-7577568 17:7674250-7674250
35 TP53 NM_000546.5(TP53):c.395A>T (p.Lys132Met) SNV Likely pathogenic 376629 rs1057519996 17:7578535-7578535 17:7675217-7675217
36 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Likely pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
37 HRAS NM_005343.4(HRAS):c.38G>C (p.Gly13Ala) SNV Likely pathogenic 376443 rs104894226 11:534285-534285 11:534285-534285
38 TP53 NM_000546.5(TP53):c.713G>C (p.Cys238Ser) SNV Likely pathogenic 376575 rs730882005 17:7577568-7577568 17:7674250-7674250
39 TP53 NM_000546.5(TP53):c.394A>C (p.Lys132Gln) SNV Likely pathogenic 376628 rs747342068 17:7578536-7578536 17:7675218-7675218
40 BRAF NM_001374258.1(BRAF):c.1526G>A (p.Gly509Glu) SNV Likely pathogenic 13974 rs121913355 7:140481402-140481402 7:140781602-140781602
41 HRAS NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Likely pathogenic 35554 rs104894228 11:534286-534286 11:534286-534286
42 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Likely pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
43 KMT2D NM_003482.3(KMT2D):c.12844C>T (p.Arg4282Ter) SNV Likely pathogenic 372805 rs1057517992 12:49425644-49425644 12:49031861-49031861
44 RECQL4 NM_004260.4(RECQL4):c.3136G>A (p.Glu1046Lys) SNV Likely pathogenic 800340 rs771349728 8:145737627-145737627 8:144512244-144512244
45 KRAS NM_004985.5(KRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 45116 rs121913240 12:25380276-25380276 12:25227342-25227342
46 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr) SNV Likely pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
47 TP53 NM_000546.5(TP53):c.815T>A (p.Val272Glu) SNV Likely pathogenic 376673 rs876660333 17:7577123-7577123 17:7673805-7673805
48 TP53 NM_000546.5(TP53):c.833C>A (p.Pro278His) SNV Likely pathogenic 376646 rs876659802 17:7577105-7577105 17:7673787-7673787
49 TP53 NM_000546.5(TP53):c.815T>G (p.Val272Gly) SNV Likely pathogenic 233323 rs876660333 17:7577123-7577123 17:7673805-7673805
50 NRAS NM_002524.5(NRAS):c.182A>T (p.Gln61Leu) SNV Likely pathogenic 375874 rs11554290 1:115256529-115256529 1:114713908-114713908

Copy number variations for Myeloma, Multiple from CNVD:

7 (show top 50) (show all 302)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13351 1 1 125000000 Gain Multiple myeloma
2 14061 1 103799708 118390708 Loss Multiple myeloma
3 14338 1 107200000 120600000 Loss and deletion Multiple myeloma
4 14696 1 110000000 184000000 Gain SELL Multiple myeloma
5 16446 1 124300000 247249719 Rearrangement Multiple myeloma
6 17400 1 142600000 156500000 Gain and amplification Multiple myeloma
7 17467 1 142902432 245422432 Gain Multiple myeloma
8 20609 1 153300000 154800000 Gain AIM2 Multiple myeloma
9 20611 1 153300000 154800000 Gain SMG5 Multiple myeloma
10 20848 1 154800000 157300000 Gain UFC1 Multiple myeloma
11 20849 1 154800000 158800000 Gain NOS1AP Multiple myeloma
12 20882 1 155000000 156500000 Gain and amplification Multiple myeloma
13 26152 1 197500000 205300000 Gain CHI3L1 Multiple myeloma
14 26153 1 197500000 205300000 Gain PTPN7 Multiple myeloma
15 26162 1 197500000 222100000 Gain GUK1 Multiple myeloma
16 29497 1 23265113 23869113 Loss Multiple myeloma
17 29829 1 236600000 249250621 Gain and amplification Multiple myeloma
18 31636 1 2900000 120700000 Gain CD53 Multiple myeloma
19 31729 1 30200000 32400000 Loss and deletion Multiple myeloma
20 31749 1 30500000 184000000 Gain Multiple myeloma
21 33943 1 50669458 53683458 Loss Multiple myeloma
22 33949 1 50700000 59000000 Loss and deletion Multiple myeloma
23 35189 1 60900000 69500000 Gain NFIA Multiple myeloma
24 36791 1 80821425 83677425 Loss Multiple myeloma
25 36969 1 84171854 96213854 Loss Multiple myeloma
26 37035 1 84700000 88100000 Gain Multiple myeloma
27 37040 1 84700000 94500000 Gain DISC1 Multiple myeloma
28 37519 1 9200000 12700000 Loss and deletion Multiple myeloma
29 37525 10 30762871 30790767 Gain MAP3K8 Multiple myeloma
30 38898 10 105800000 114900000 Loss and deletion Multiple myeloma
31 40402 10 127500000 135534747 Loss and deletion Multiple myeloma
32 41379 10 17300000 22600000 Gain and amplification Multiple myeloma
33 48571 11 100828925 102320925 Loss ANGPTL5 Multiple myeloma
34 48572 11 100828925 102320925 Loss BIRC2 Multiple myeloma
35 48573 11 100828925 102320925 Loss BIRC3 Multiple myeloma
36 48574 11 100828925 102320925 Loss CEP126 Multiple myeloma
37 48575 11 100828925 102320925 Loss MMP1 Multiple myeloma
38 48576 11 100828925 102320925 Loss MMP10 Multiple myeloma
39 48577 11 100828925 102320925 Loss MMP12 Multiple myeloma
40 48578 11 100828925 102320925 Loss MMP13 Multiple myeloma
41 48579 11 100828925 102320925 Loss MMP20 Multiple myeloma
42 20700 1 1536308 6536308 Loss Multiple myeloma
43 48580 11 100828925 102320925 Loss MMP27 Multiple myeloma
44 48581 11 100828925 102320925 Loss MMP3 Multiple myeloma
45 48582 11 100828925 102320925 Loss MMP7 Multiple myeloma
46 48583 11 100828925 102320925 Loss MMP8 Multiple myeloma
47 48584 11 100828925 102320925 Loss TMEM123 Multiple myeloma
48 48585 11 100828925 102320925 Loss TRPC6 Multiple myeloma
49 48586 11 100828925 102320925 Loss YAP1 Multiple myeloma
50 49668 11 110000000 112800000 Gain POU2AF1 Multiple myeloma
Sources

Expression for Myeloma, Multiple

About this section
Search GEO for disease gene expression data for Myeloma, Multiple.
Sources

Pathways for Myeloma, Multiple

About this section

Pathways related to Myeloma, Multiple according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Myeloma, Multiple according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.77 MIR32 MIR25 MIR19A MIR181A2 MIR15A MIR106B
2
Bladder cancer 36 1
11.2 KRAS FGFR3 CCND1
3
miRNAs involved in DNA damage response 1
10.96 MIR93 MIR25 MIR106B CCND1
4
MNAR-PELP1 and Estrogen Receptor Interaction 63
10.68 KRAS CCND1
5
LncRNA-mediated mechanisms of therapeutic resistance 1